Jazz Pharmaceuticals Stock Forecast, Price & News

Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

Is Jazz Pharmaceuticals a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Jazz Pharmaceuticals stock.
View analyst ratings for Jazz Pharmaceuticals or view top-rated stocks.

How has Jazz Pharmaceuticals' stock price been impacted by COVID-19?

Jazz Pharmaceuticals' stock was trading at $108.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, JAZZ stock has increased by 12.1% and is now trading at $121.16.
View which stocks have been most impacted by COVID-19.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Jazz Pharmaceuticals.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted its quarterly earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.60 by $1.60. The specialty pharmaceutical company earned $838.12 million during the quarter, compared to analyst estimates of $829.98 million. Jazz Pharmaceuticals had a negative net margin of 5.62% and a positive trailing twelve-month return on equity of 21.43%. During the same quarter in the prior year, the business posted $3.86 EPS.
View Jazz Pharmaceuticals' earnings history.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals updated its FY 2021 earnings guidance on Tuesday, November, 30th. The company provided earnings per share guidance of $15.100-$15.800 for the period, compared to the Thomson Reuters consensus estimate of $14.520. The company issued revenue guidance of $3.02 billion-$3.10 billion, compared to the consensus revenue estimate of $3.09 billion.

What price target have analysts set for JAZZ?

15 Wall Street analysts have issued 1 year target prices for Jazz Pharmaceuticals' shares. Their forecasts range from $174.00 to $250.00. On average, they anticipate Jazz Pharmaceuticals' stock price to reach $212.46 in the next twelve months. This suggests a possible upside of 75.4% from the stock's current price.
View analysts' price targets for Jazz Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the following people:

• Bruce C. Cozadd, Chairman & Chief Executive Officer (LinkedIn Profile)
• Daniel N. Swisher, President
• Christopher John Tovey, Chief Operating Officer & Executive Vice President
• Renée D. Galá, Chief Financial Officer & Executive Vice President
• Robert Iannone, Chief Medical Officer, EVP-Research & Development

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals CEO Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among Jazz Pharmaceuticals' employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Jazz Pharmaceuticals' key competitors?

Some companies that are related to Jazz Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Perrigo (PRGO), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of JAZZ's competitors.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.20%), Wellington Management Group LLP (3.52%), Renaissance Technologies LLC (3.26%), Polaris Capital Management LLC (3.20%), LSV Asset Management (3.06%) and Dimensional Fund Advisors LP (1.54%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Bruce C Cozadd, Elmar Schnee, Finbar Larkin, James E Flynn, Kenneth W O'keefe, Kim Sablich, Michael Patrick Miller, Patricia Carr, Patrick G Enright, Paul L Berns and Seamus Mulligan.
View institutional ownership trends for Jazz Pharmaceuticals.

Which major investors are selling Jazz Pharmaceuticals stock?

JAZZ stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jennison Associates LLC, Arrowstreet Capital Limited Partnership, Goldman Sachs Group Inc., KBC Group NV, LSV Asset Management, PGGM Investments, and Geode Capital Management LLC. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Elmar Schnee, Finbar Larkin, Kim Sablich, and Patricia Carr.
View insider buying and selling activity for Jazz Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Jazz Pharmaceuticals stock?

JAZZ stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Polaris Capital Management LLC, Farallon Capital Management LLC, Wellington Management Group LLP, Bellevue Group AG, Morgan Stanley, Brandywine Global Investment Management LLC, and Polar Capital Holdings Plc. Company insiders that have bought Jazz Pharmaceuticals stock in the last two years include James E Flynn, and Seamus Mulligan.
View insider buying and selling activity for Jazz Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $121.16.

How much money does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals has a market capitalization of $7.45 billion and generates $2.36 billion in revenue each year. The specialty pharmaceutical company earns $238.62 million in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does Jazz Pharmaceuticals have?

Jazz Pharmaceuticals employs 1,940 workers across the globe.

Does Jazz Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.

When was Jazz Pharmaceuticals founded?

Jazz Pharmaceuticals was founded in 2003.

What is Jazz Pharmaceuticals' official website?

The official website for Jazz Pharmaceuticals is www.jazzpharma.com.

Where are Jazz Pharmaceuticals' headquarters?

Jazz Pharmaceuticals is headquartered at FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at [email protected], or via fax at 353-1634-7850.